Enlivex Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2016 - 2019
Net Income	-15.01	-29.07	-31.06	-14.47	-11.82	Upgrade
Depreciation & Amortization	0.55	0.84	0.78	0.55	0.29	Upgrade
Loss (Gain) From Sale of Assets	0.88	4.22	-	-	-	Upgrade
Loss (Gain) From Sale of Investments	-0.56	-0.34	1.98	-5.59	-	Upgrade
Stock-Based Compensation	2.07	1.95	2.71	2.91	0.67	Upgrade
Other Operating Activities	0.3	0.7	0.83	0.41	0.17	Upgrade
Change in Accounts Payable	-0.02	-1.12	1.17	0.44	0.04	Upgrade
Change in Other Net Operating Assets	-1.2	-0.7	-0.36	-1.8	-0.34	Upgrade
Operating Cash Flow	-13.01	-23.52	-23.95	-17.54	-11.01	Upgrade
Capital Expenditures	-0.1	-0.24	-8.12	-1.63	-1.02	Upgrade
Sale of Property, Plant & Equipment	2.29	0.13	-	-	-	Upgrade
Investment in Securities	6.87	-25.87	70.65	-36.78	-19.96	Upgrade
Investing Cash Flow	9.06	-25.97	62.52	-38.41	-20.98	Upgrade
Issuance of Common Stock	7.1	0.51	0.15	65.44	35.58	Upgrade
Other Financing Activities	-0.65	-0.15	-	-4.46	-2.5	Upgrade
Financing Cash Flow	6.45	0.36	0.15	60.98	33.08	Upgrade
Foreign Exchange Rate Adjustments	-	-	-	-0.41	0.39	Upgrade
Net Cash Flow	2.51	-49.13	38.72	4.62	1.49	Upgrade
Free Cash Flow	-13.11	-23.76	-32.08	-19.17	-12.03	Upgrade
Free Cash Flow Per Share	-0.64	-1.28	-1.74	-1.07	-0.91	Upgrade
Levered Free Cash Flow	-5.41	-17.77	-18.68	-10.19	-5.87	Upgrade
Unlevered Free Cash Flow	-5.41	-17.77	-18.68	-10.19	-5.87	Upgrade
Change in Net Working Capital	-1.8	4.6	-2.08	-0.03	-0.31	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.